Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenograftsGaspar J. Kitange, Jann N. Sarkaria, Brett L. Carlson et al.|Neuro-Oncology|2008Cited by 387
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177Paul D. Brown, Jan C. Buckner, Sunil Krishnan et al.|Journal of Clinical Oncology|2008Cited by 275
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panelJann N. Sarkaria, C. David James, Lin Yang et al.|Molecular Cancer Therapeutics|2007Cited by 203
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cellsLing Cen, Jann N. Sarkaria, Brett L. Carlson et al.|Neuro-Oncology|2012Cited by 187
Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma XenograftsGaspar J. Kitange, Jann N. Sarkaria, Jenny L. Pokorny et al.|Clinical Cancer Research|2012Cited by 151